-+ 0.00%
-+ 0.00%
-+ 0.00%

Abivax Provides 2026 Corporate Outlook

Barchart·01/07/2026 15:05:00
Listen to the news

Abivax Provides 2026 Corporate Outlook

PARIS, France – January 7, 2026 – 10:05 PM CETAbivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced its 2026 corporate outlook, highlighting new market insights, progress in the ABTECT-UC and ENHANCE-CD trials, and advances in its therapeutic pipeline. Updates from the ABTECT Phase 3 maintenance trial evaluating obefazimod for the treatment of moderate-to-severely active UC reinforce the therapy’s safety profile and inform potential future combination strategies.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.